Core Viewpoint - As of August 13, 2023, AAPG's stock price increased by 3.23% to $41.5 per share, with a total market capitalization of $3.858 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a growth of 56.2% year-on-year [1][3]. Company Overview - AAPG is a biopharmaceutical company based in China with a global focus, dedicated to developing innovative drugs for the treatment of cancer, hepatitis B, and age-related diseases [2]. - The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [2]. - AAPG has developed a proprietary drug design platform targeting protein-protein interactions and is at the forefront of new drug development in the apoptosis pathway [2]. Product Pipeline - The company has established a pipeline of nine Class 1 small molecule new drugs that have entered clinical development, including inhibitors targeting key proteins in the apoptosis pathway such as Bcl-2, IAP, and MDM2-p53 [2]. - AAPG is the only innovative company globally with clinical development products in all key proteins of the apoptosis pathway [2]. - The core product, Aorebatin (brand name: Nairike), has been approved in China and is included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022) [2]. Clinical Trials and Regulatory Approvals - The company is conducting over 40 clinical trials across China, the United States, Australia, and Europe [2]. - AAPG has received multiple designations from the FDA, including orphan drug status and fast track designation for four investigational new drugs [2]. - The company has undertaken several national science and technology major projects, including five under the "Major New Drug Creation" initiative [2]. Collaborations and Talent - AAPG has established global collaborations with leading biotechnology and pharmaceutical companies and academic institutions, including UNITY, MD Anderson, Mayo Clinic, Dana-Farber Cancer Institute, Merck, AstraZeneca, and Pfizer [2]. - The company has built an international team with extensive experience in original drug research and clinical development [2].

Core Viewpoint - The stock price of HeYu-B (02256) has surged nearly 200% year-to-date, driven by favorable policies and a warming investment climate in the Hong Kong innovative drug sector, leading to increased emphasis on the commercialization capabilities of innovative drug companies [1][2]. Group 1: Stock Performance and Market Recognition - On August 11, the company's stock price surpassed the IPO price of HKD 12.46, closing up 5.93%, and reached a new high of HKD 13.67 the following day [1]. - HeYu was included in the MSCI Global Small Cap Index, which tracks over USD 17 trillion in assets, enhancing its market liquidity and international visibility [4]. Group 2: Innovation and Financial Performance - HeYu's core product, Pimicotinib, is the first Chinese-developed CSF-1R inhibitor entering global Phase III clinical trials, with significant potential in various indications [5][6]. - The company secured a high-value partnership with Merck, receiving an upfront payment of USD 70 million, which is expected to lead to its first annual profit in 2024 [5][7]. - HeYu has maintained around HKD 2 billion in cash reserves over the past three years, ensuring financial stability and supporting ongoing R&D efforts [9]. Group 3: Pipeline and Future Prospects - HeYu's pipeline includes multiple innovative drugs, with Pimicotinib and the FGFR4 inhibitor Irpagratinib being highlighted as potential blockbuster products [10]. - The company has presented promising preclinical results at major conferences, showcasing its advancements in small molecule innovation [10]. - HeYu's stock buyback program, amounting to HKD 200 million, reflects its commitment to returning value to shareholders while maintaining a low price-to-sales (PS) ratio of 13.38, indicating significant growth potential [11].

Group 1 - The core viewpoint highlights the rapid enhancement of the "first industry" capability in Suzhou Industrial Park, driven by precise policy support and deep capital empowerment, particularly in the biopharmaceutical sector [1] - In 2023, six innovative Class I drugs were approved for market release in the park, accounting for approximately 20% of the national total, showcasing the growing "innovation source" effect in biomedicine [2] - The park has attracted over 2,000 related enterprises since 2006, with a projected output value of 165.5 billion yuan in 2024, emphasizing its strategic focus on biomedicine and health industries [1] Group 2 - The "Biopharmaceutical and Health Industry Leap Action Plan (2025-2027)" aims to cultivate five international leading enterprises, 50 leading companies in niche markets, and 100 key products with annual sales exceeding 100 million yuan by 2027 [1] - The capital market has shown active performance, with companies like Sifen Technology and Ascentage Pharma successfully listing on various stock exchanges, indicating strong market confidence in the park's biopharmaceutical capabilities [2] - The integration of artificial intelligence in research and development is reshaping the paradigm, with significant improvements in efficiency and cost reduction in drug development processes [3]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.02%, with notable stock performances including Jingtai Holdings (02228) up 7.38% and Fosun Pharma (02196) up 6.00% [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.52%, reaching a latest price of 0.97 yuan, with a trading volume of 240.45 million yuan and a turnover rate of 0.62% [3] - Jingtai Holdings announced an expected comprehensive income of no less than 500 million yuan for the six months ending June 30, 2025, representing an increase of at least 387% compared to the same period in 2024 [3] Group 2 - The Hong Kong Innovative Drug Selection ETF reached a new high in scale at 385 million yuan and a new high in shares at 399 million [4] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 22.93 million yuan, totaling 42.28 million yuan [4] - The ETF's management fee is 0.50% and the custody fee is 0.10%, which are among the lowest in comparable funds [5] Group 3 - The HSSCPB index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5] - The top ten weighted stocks in the HSSCPB index account for 78.05% of the total index weight, including companies like BeiGene (06160) and WuXi Biologics (02269) [5]

Market Performance - On August 11, U.S. stock indices experienced slight declines, with the Dow Jones Industrial Average falling by 0.45%, the S&P 500 down by 0.25%, and the Nasdaq down by 0.3% [1][3]. - Major technology stocks mostly declined, with the Wind U.S. Technology Seven Giants Index decreasing by 0.22%. Notable individual stock movements included Apple dropping over 0.8%, while Tesla rose over 2.8% for a four-day increase [5]. International Commodities - International precious metal futures generally fell on August 11, with COMEX gold futures main contract down by 2.8% to $3,393.7 per ounce, and COMEX silver futures down by 2.33% to $37.645 per ounce [2][7]. - Oil prices saw a slight increase, with light crude oil futures for September delivery rising by 8 cents to $63.96 per barrel, a 0.13% increase, and Brent crude oil futures for October delivery up by 4 cents to $66.63 per barrel, a 0.06% increase [7]. Chinese Stocks - The Nasdaq China Golden Dragon Index fell by 0.29%, with notable declines in popular Chinese stocks such as QuantumScape and Ascentage Pharma, which dropped over 4%. However, Xpeng Motors saw an increase of nearly 6% [6]. Geopolitical Developments - U.S. President Trump announced a "test meeting" with Russian President Putin scheduled for August 15 in Alaska, indicating that the outcome could be "good or bad" but expressing hope for "constructive dialogue" [2][8]. - Trump mentioned the possibility of arranging a meeting between Ukrainian President Zelensky and Putin following their discussions, suggesting potential increases in U.S.-Russia trade if an agreement is reached regarding Ukraine [8][9].

Market Performance - On August 11, US stock indices experienced slight declines, with the Dow Jones Industrial Average falling by 0.45%, the S&P 500 down by 0.25%, and the Nasdaq decreasing by 0.3% [1][3]. - Major technology stocks mostly declined, with the US Tech Giants Index dropping by 0.22%. Notable individual stock movements included Apple down over 0.8%, while Tesla rose over 2.8% for a four-day increase [5]. Commodity Market - International precious metal futures generally fell, with COMEX gold futures main contract dropping by 2.8% to $3393.7 per ounce, and COMEX silver futures down by 2.33% to $37.645 per ounce [2][6]. - Oil prices saw a slight increase, with light crude oil futures for September rising by 8 cents to $63.96 per barrel, a 0.13% increase, and Brent crude oil for October up by 4 cents to $66.63 per barrel, a 0.06% increase [6]. Chinese Stocks - The Nasdaq Golden Dragon China Index fell by 0.29%, with notable declines in popular Chinese stocks such as QuantumScape and Ascentage Pharma, which dropped over 4%. However, Xpeng Motors saw an increase of nearly 6% [6]. Geopolitical Developments - President Trump announced a "test meeting" with President Putin scheduled for August 15 in Alaska, suggesting that the outcome could be either positive or negative, but expressing hope for constructive dialogue [2][7]. - Trump indicated that he hopes to arrange a meeting between Ukrainian President Zelensky and Putin following the Alaska meeting, with the possibility of a trilateral meeting involving the US, Russia, and Ukraine [7][8].

（股份代號：6855） 董事會會議通告 亞盛醫藥集團（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）謹 此宣佈，本公司將於2025年8月20日（星期三）舉行董事會會議，藉以考慮及（如 合適）批准（其中包括）本集團截至2025年6月30日止六個月之未經審核中期業 績，以及其發佈。 承董事會命 亞盛醫藥集團 主席兼執行董事 楊大俊博士 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 （於開曼群島註冊成立的有限公司） 中華人民共和國蘇州，2025年8月8日 於本公告日期，董事會包括主席兼執行董事楊大俊博士；非執行董事王少萌博士 及呂大忠博士；以及獨立非執行董事葉長青先生、任為先生、David Sidransky博 士、Marina S. Bozilenko女士、Debra Yu博士及Marc E. Lippman, MD。 ...

Core Viewpoint - The recent pullback in the innovative drug sector does not indicate a peak, as the underlying logic differs from previous market cycles, particularly the 2021 bubble [2][3]. Group 1: Current Market Conditions - The current rise in innovative drugs is supported by strong fundamentals, contrasting with the previous bubble driven by capital [4][5]. - Key drivers include the ability to generate revenue from overseas markets, gradual improvement in domestic drug consumption capacity, favorable policy changes, and advancements in technology [5][6][7]. - The Chinese market is expected to see a significant increase in the approval speed for innovative drugs, with the average approval time reduced from 24 months to 12 months [6]. Group 2: Investment Opportunities - The innovative drug market is likely to experience a long-term trend supported by various factors, including engineering talent, policy benefits, technological breakthroughs, and capital support [7]. - Companies in the sector face challenges in realizing their pipeline values, necessitating careful evaluation of current market valuations against potential future values [8][11]. - The market has shifted from negative expectations to normal expectations, leading to substantial price increases for many companies that were previously undervalued [9][10]. Group 3: Specific Company Analysis - For instance, He Yu Pharmaceutical has a market cap of approximately 70 billion HKD, with cash reserves of 23 billion RMB and pipeline values potentially exceeding 40 billion RMB [12][14]. - The company's lead pipeline candidate, Pimicotinib, has high market expectations, with projected peak sales exceeding 2 billion USD [12][14]. - Other companies in the sector exhibit similar characteristics, where short-term price increases may obscure the true intrinsic value of their businesses [17]. Group 4: Future Trends and Strategies - The market is expected to transition from a broad-based rally to a more differentiated performance, emphasizing the importance of identifying companies with strong fundamentals [18]. - Business Development (BD) will continue to be a critical factor, with companies focusing on reliable technologies and partnerships to drive growth [18][19]. - Pre-commercial companies are also seen as attractive investments, as their valuations can significantly increase upon achieving commercialization milestones [23][24]. Group 5: Industry Outlook - The Chinese innovative drug industry is undergoing a critical transformation, with improved R&D capabilities and capital efficiency, comparable to strong sectors like photovoltaics and new energy [25].

Core Viewpoint - Morgan Stanley reports that Ascentage Pharma (06855) has seen a year-to-date stock price increase of approximately 83%, aligning with the strong performance of the Hang Seng Healthcare Index, which has risen about 78% [1] Group 1: Stock Performance and Target Price - Morgan Stanley has updated its model for Ascentage Pharma following discussions at the recent Sino-US Biotechnology Forum, considering the latest developments in the company's product pipeline [1] - The target price for Ascentage Pharma has been significantly raised by 79% from the previous HKD 52 to HKD 93, while maintaining an "Overweight" rating [1] Group 2: Key Assets and Sales Forecast - The firm remains optimistic about the company's key assets, "olverembatinib" and "lisaftoclax," which are expected to drive strong product sales this year [1] - There is an improved outlook for the overseas potential of "lisaftoclax," particularly in light of the failure of "venetoclax" to demonstrate overall survival benefits in myelodysplastic syndromes (MDS), along with the drug's market approval scope in China exceeding expectations [1]

Core Viewpoint - As of August 7, 2023, AAPG's stock price increased by 2.38% to $43.00 per share, with a total market capitalization of $3.997 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a growth of 56.2% year-on-year [1][2]. Group 1: Company Overview - AAPG is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases [2]. - The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [2]. - AAPG has established a proprietary drug design platform targeting protein-protein interactions and is at the forefront of developing new drugs in the apoptosis pathway [2]. Group 2: Product Pipeline and Clinical Development - The company has a pipeline of nine Class 1 small molecule new drugs that have entered clinical development, including inhibitors targeting key proteins in the apoptosis pathway [2]. - AAPG is conducting over 40 clinical trials across China, the United States, Australia, and Europe [2]. - The core product, Orebatinib (brand name: Nairike), has received priority review and breakthrough therapy designation from the China National Medical Products Administration and has been approved for sale in China [2]. Group 3: Regulatory Approvals and Collaborations - Orebatinib has been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022) in China and has received multiple designations from the FDA, including orphan drug status and fast track designation [2]. - AAPG has been involved in several national science and technology major projects, including five projects under the "Major New Drug Creation" initiative [2]. - The company has established global collaborations with leading biotech and pharmaceutical companies and academic institutions, enhancing its research and development capabilities [2].